e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study
Brandon J. Webb, Jeff Sorensen, Al Jephson, Ian Mecham, Nathan C. Dean
Source:
Eur Respir J, 54 (1) 1900057; 10.1183/13993003.00057-2019
Journal Issue:
July
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Brandon J. Webb, Jeff Sorensen, Al Jephson, Ian Mecham, Nathan C. Dean. Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study. Eur Respir J, 54 (1) 1900057; 10.1183/13993003.00057-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia
Source: International Congress 2018 – Improving the outcomes of community-acquired pneumonia
Year: 2018
The extent of microbiological testing and antibiotic de-escalation in adults with community-acquired pneumonia: a retrospective cohort study.
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018
Influence of adherence to clinical guidelines in empiric antibiotics choice on outcomes of community-acquired pneumonia in hospitalized Belarussian patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens
Source: Eur Respir J 2002; 20: 432-439
Year: 2002
Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives
Source: Eur Respir J 2004; 24: Suppl. 48, 185s
Year: 2004
Trends in empiric antimicrobial therapy and efficiency of care for community-acquired pneumonia in hospitalized Belarussian patients
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006
The impact of adherence to guidelines for hospitalized community-acquired pneumonia on health outcomes and mortality: A retrospective cohort study
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015
Antibiotic resistance and clinical outcomes: the CAPNETZ experience
Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections
Year: 2006
The effects of antibiotic therapy at the pre-hospital stage on the in-hospital mortality in adults with community-acquired pneumonia in Russia: observational study results.
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
Determinants of performance of indicators on antibiotic use in community-acquired pneumonia (CAP) at hospitals
Source: Eur Respir J 2005; 26: Suppl. 49, 638s
Year: 2005
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
Barriers to adherence to key indicators of antibiotic use for community-acquired pneumonia: a qualitative study
Source: Eur Respir J 2005; 26: Suppl. 49, 258s
Year: 2005
Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 33-39
Year: 2007
Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review
Source: Eur Respir J 2008; 31: 625-632
Year: 2008
Guideline-concordant therapy and outcomes in healthcare-associated pneumonia
Source: Eur Respir J 2011; 38: 878-887
Year: 2011
Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006
The presence of diabetes does not influence clinical outcomes in patients with community-acquired pneumonia: results from the community-acquired pneumonia organization (CAPO) international cohort study
Source: Annual Congress 2007 - Severity scores and comorbidities in community-acquired pneumonia
Year: 2007
Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia
Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept